Skip to main content
Erschienen in: European Radiology 2/2024

17.08.2023 | Gastrointestinal

LI-RADS threshold growth based on tumor growth rate can improve the diagnosis of hepatocellular carcinoma ≤ 3.0 cm

verfasst von: Boryeong Jeong, Se Jin Choi, Sang Hyun Choi, Hyeon Ji Jang, Jae Ho Byun, Hyung Jin Won, Yong Moon Shin

Erschienen in: European Radiology | Ausgabe 2/2024

Einloggen, um Zugang zu erhalten

Abstract

Objective

Despite the revision of threshold growth (TG) in the Liver Imaging Reporting and Data System (LI-RADS) version 2018, the appropriate time period between the two examinations for TG has not been determined. We compared the accuracy of LI-RADS with TG based on tumor growth rate for the diagnosis of hepatocellular carcinoma (HCC) with that of LI-RADS v2018 based on the original TG.

Methods

Patients who underwent preoperative MRI for focal solid lesions (≤ 3.0 cm) were retrospectively evaluated. Three readers measured the size of each lesion on prior CT/MRI and index MRI, with tumor growth rate defined as the percent change in lesion size per month. In addition to the original TG (≥ 50% size increase within ≤ 6 months), the modified TG based on tumor growth rates ≥ 10%/month (TG-10%), ≥ 20%/month (TG-20%), and ≥ 30%/month (TG-30%) were evaluated. The accuracies of these evaluation methods for LI-RADS category 5 HCC were compared using generalized estimation equations.

Results

A total of 508 lesions from 370 patients were evaluated. Compared with LI-RADS v2018 with the original TG, the accuracy of LI-RADS with TG-10% was significantly higher (85.0% vs. 80.7%, p < .001), whereas the accuracies of LI-RADS with TG-20% (81.3% vs. 80.7%, p = .404) and TG-30% (79.3% vs. 80.7%, p = .052) were not significant. The sensitivity of LI-RADS with TG-10% was higher than that of LI-RADS v2018 (79.0% vs. 72.5%, p < .001), whereas their specificities were not significantly different (96.6% vs. 96.6%, p > .999).

Conclusion

TG-10% improved the sensitivity of LI-RADS by detecting additional hepatocellular carcinomas underestimated due to short-term follow-up.

Clinical relevance statement

Threshold growth based on tumor growth rate can be clinically useful in the diagnosis of hepatocellular carcinoma, by improving the sensitivity of LI-RADS.

Key Points

The diagnostic accuracy of Liver Imaging Reporting and Data System (LI-RADS) v2018 was not significantly affected by the time interval between prior and index assessments of threshold growth.
In the 334 hepatocellular carcinomas, the frequency of threshold growth was significantly higher using tumor growth rate ≥ 10%/month (TG-10%) than original threshold growth (53.3% vs. 18.0%, p < .001).
Compared with LI-RADS v2018 with the original threshold growth, LI-RADS with TG-10% had significantly higher accuracy (85.0% vs. 80.7%, p < .001) and sensitivity (79.0% vs. 72.5%, p < .001) but a similar specificity (96.6% vs. 96.6%, p > .999).
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Marrero JA, Kulik LM, Sirlin CB et al (2018) Diagnosis, staging, and management of hepatocellular carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 68:723–750CrossRefPubMed Marrero JA, Kulik LM, Sirlin CB et al (2018) Diagnosis, staging, and management of hepatocellular carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 68:723–750CrossRefPubMed
2.
Zurück zum Zitat Kim DH, Choi SH, Park SH et al (2019) Meta-analysis of the accuracy of Liver Imaging Reporting and Data System category 4 or 5 for diagnosing hepatocellular carcinoma. Gut 68:1719–1721CrossRefPubMed Kim DH, Choi SH, Park SH et al (2019) Meta-analysis of the accuracy of Liver Imaging Reporting and Data System category 4 or 5 for diagnosing hepatocellular carcinoma. Gut 68:1719–1721CrossRefPubMed
3.
Zurück zum Zitat Kim YY, Lee S, Shin J et al (2021) Diagnostic performance of liver imaging reporting and data system version 2017 versus version 2018 for hepatocellular carcinoma: a systematic review and meta-analysis of comparative studies. J Magn Reson Imaging 54:1912–1919CrossRefPubMed Kim YY, Lee S, Shin J et al (2021) Diagnostic performance of liver imaging reporting and data system version 2017 versus version 2018 for hepatocellular carcinoma: a systematic review and meta-analysis of comparative studies. J Magn Reson Imaging 54:1912–1919CrossRefPubMed
4.
Zurück zum Zitat Shingaki N, Tamai H, Mori Y et al (2013) Serological and histological indices of hepatocellular carcinoma and tumor volume doubling time. Mol Clin Oncol 1:977–981CrossRefPubMedPubMedCentral Shingaki N, Tamai H, Mori Y et al (2013) Serological and histological indices of hepatocellular carcinoma and tumor volume doubling time. Mol Clin Oncol 1:977–981CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Wald C, Russo MW, Heimbach JK, Hussain HK, Pomfret EA, Bruix J (2013) New OPTN/UNOS policy for liver transplant allocation: standardization of liver imaging, diagnosis, classification, and reporting of hepatocellular carcinoma. Radiology 266:376–382CrossRefPubMed Wald C, Russo MW, Heimbach JK, Hussain HK, Pomfret EA, Bruix J (2013) New OPTN/UNOS policy for liver transplant allocation: standardization of liver imaging, diagnosis, classification, and reporting of hepatocellular carcinoma. Radiology 266:376–382CrossRefPubMed
7.
Zurück zum Zitat Choi SJ, Choi SH, Kim DW et al (2023) Value of threshold growth as a major diagnostic feature of hepatocellular carcinoma in LI-RADS. J Hepatol 78:596–603CrossRefPubMed Choi SJ, Choi SH, Kim DW et al (2023) Value of threshold growth as a major diagnostic feature of hepatocellular carcinoma in LI-RADS. J Hepatol 78:596–603CrossRefPubMed
9.
Zurück zum Zitat Lee YJ, Lee JM, Lee JS et al (2015) Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging-a systematic review and meta-analysis. Radiology 275:97–109CrossRefPubMed Lee YJ, Lee JM, Lee JS et al (2015) Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging-a systematic review and meta-analysis. Radiology 275:97–109CrossRefPubMed
10.
Zurück zum Zitat Yoon SH, Lee JM, So YH et al (2009) Multiphasic MDCT enhancement pattern of hepatocellular carcinoma smaller than 3 cm in diameter: tumor size and cellular differentiation. AJR Am J Roentgenol 193:W482-489CrossRefPubMed Yoon SH, Lee JM, So YH et al (2009) Multiphasic MDCT enhancement pattern of hepatocellular carcinoma smaller than 3 cm in diameter: tumor size and cellular differentiation. AJR Am J Roentgenol 193:W482-489CrossRefPubMed
11.
Zurück zum Zitat van den Bos IC, Hussain SM, Dwarkasing RS et al (2007) MR imaging of hepatocellular carcinoma: relationship between lesion size and imaging findings, including signal intensity and dynamic enhancement patterns. J Magn Reson Imaging 26:1548–1555CrossRefPubMed van den Bos IC, Hussain SM, Dwarkasing RS et al (2007) MR imaging of hepatocellular carcinoma: relationship between lesion size and imaging findings, including signal intensity and dynamic enhancement patterns. J Magn Reson Imaging 26:1548–1555CrossRefPubMed
12.
Zurück zum Zitat Park JH, Chung YE, Seo N, Choi JY, Park MS, Kim MJ (2021) Should threshold growth be considered a major feature in the diagnosis of hepatocellular carcinoma using LI-RADS? Korean J Radiol 22:1628–1639CrossRefPubMedPubMedCentral Park JH, Chung YE, Seo N, Choi JY, Park MS, Kim MJ (2021) Should threshold growth be considered a major feature in the diagnosis of hepatocellular carcinoma using LI-RADS? Korean J Radiol 22:1628–1639CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Choi JY, Ha J, Choi SH, Kang HJ, Kim SY, Kim KW (2022) Comparison of gadoxetate disodium-enhanced MRI sequences for measuring hepatic observation size and its implication of LI-RADS classification. Abdom Radiol (NY) 47:1024–1031CrossRefPubMed Choi JY, Ha J, Choi SH, Kang HJ, Kim SY, Kim KW (2022) Comparison of gadoxetate disodium-enhanced MRI sequences for measuring hepatic observation size and its implication of LI-RADS classification. Abdom Radiol (NY) 47:1024–1031CrossRefPubMed
14.
Zurück zum Zitat Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159–174CrossRefPubMed Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159–174CrossRefPubMed
15.
Zurück zum Zitat Koo TK, Li MY (2016) A guideline of selecting and reporting intraclass correlation coefficients for reliability research. J Chiropr Med 15:155–163CrossRefPubMedPubMedCentral Koo TK, Li MY (2016) A guideline of selecting and reporting intraclass correlation coefficients for reliability research. J Chiropr Med 15:155–163CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Tanaka M, Fernández-del Castillo C, Kamisawa T et al (2017) Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology 17:738–753CrossRefPubMed Tanaka M, Fernández-del Castillo C, Kamisawa T et al (2017) Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology 17:738–753CrossRefPubMed
17.
Zurück zum Zitat Burke J, Brown P, Quyn A, Lambie H, Tolan D, Sagar P (2020) Tumour growth rate of carcinoma of the colon and rectum: retrospective cohort study. BJS Open 4:1200–1207CrossRefPubMedPubMedCentral Burke J, Brown P, Quyn A, Lambie H, Tolan D, Sagar P (2020) Tumour growth rate of carcinoma of the colon and rectum: retrospective cohort study. BJS Open 4:1200–1207CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Dromain C, Pavel ME, Ruszniewski P et al (2019) Tumor growth rate as a metric of progression, response, and prognosis in pancreatic and intestinal neuroendocrine tumors. BMC Cancer 19:66CrossRefPubMedPubMedCentral Dromain C, Pavel ME, Ruszniewski P et al (2019) Tumor growth rate as a metric of progression, response, and prognosis in pancreatic and intestinal neuroendocrine tumors. BMC Cancer 19:66CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Kamath A, Roudenko A, Hecht E et al (2019) CT/MR LI-RADS 2018: clinical implications and management recommendations. Abdom Radiol (NY) 44:1306–1322CrossRefPubMed Kamath A, Roudenko A, Hecht E et al (2019) CT/MR LI-RADS 2018: clinical implications and management recommendations. Abdom Radiol (NY) 44:1306–1322CrossRefPubMed
20.
Zurück zum Zitat Fowler KJ, Potretzke TA, Hope TA, Costa EA, Wilson SR (2018) LI-RADS M (LR-M): definite or probable malignancy, not specific for hepatocellular carcinoma. Abdom Radiol (NY) 43:149–157CrossRefPubMed Fowler KJ, Potretzke TA, Hope TA, Costa EA, Wilson SR (2018) LI-RADS M (LR-M): definite or probable malignancy, not specific for hepatocellular carcinoma. Abdom Radiol (NY) 43:149–157CrossRefPubMed
21.
Zurück zum Zitat Kim DH, Choi SH, Park SH et al (2020) Liver imaging reporting and data system category M: a systematic review and meta-analysis. Liver Int 40:1477–1487CrossRefPubMed Kim DH, Choi SH, Park SH et al (2020) Liver imaging reporting and data system category M: a systematic review and meta-analysis. Liver Int 40:1477–1487CrossRefPubMed
Metadaten
Titel
LI-RADS threshold growth based on tumor growth rate can improve the diagnosis of hepatocellular carcinoma ≤ 3.0 cm
verfasst von
Boryeong Jeong
Se Jin Choi
Sang Hyun Choi
Hyeon Ji Jang
Jae Ho Byun
Hyung Jin Won
Yong Moon Shin
Publikationsdatum
17.08.2023
Verlag
Springer Berlin Heidelberg
Erschienen in
European Radiology / Ausgabe 2/2024
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-023-10092-6

Weitere Artikel der Ausgabe 2/2024

European Radiology 2/2024 Zur Ausgabe

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Klinikreform soll zehntausende Menschenleben retten

15.05.2024 Klinik aktuell Nachrichten

Gesundheitsminister Lauterbach hat die vom Bundeskabinett beschlossene Klinikreform verteidigt. Kritik an den Plänen kommt vom Marburger Bund. Und in den Ländern wird über den Gang zum Vermittlungsausschuss spekuliert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.